Valbiotis invited to present clinical results from the TOTUM•63 Phase II/III REVERSE-IT study in prediabetes and type 2 diabetes at the American Diabetes Association’s 84th Scientific Sessions.
Being invited to deliver an oral presentation at the world's leading diabetes congress (June 21-24) is a clear indication of clinical recognition. We also present the results of the TOTUM•63 mode-of-action clinical study carried out with Laval University's Institute of Nutrition and Functional Foods (INAF), in association with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ).
See the poster on the mode of action 